New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 25, 2013
07:31 EDTCBSTCubist: Phase 3 ceftolozane/tazobactam trial met primary endpoint
Cubist Pharmaceuticals announced top-line results from the company’s pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections. Ceftolozane/tazobactam met its primary endpoint of statistical non-inferiority compared to levofloxacin. The primary endpoint is a composite of microbiological eradication and clinical cure rate at 5 - 9 days after end of therapy. The 95% confidence interval around the treatment difference had lower and upper bounds of 2.3% and 14.6%, respectively, favoring ceftolozane/tazobactam. Results of the secondary analyses were consistent with and supportive of the primary outcome. Although this trial was not prospectively designed to demonstrate superiority, the finding that the lower bound of the 95% confidence interval around the positive treatment differences in favor of ceftolozane/tazobactam was greater than zero indicated statistical superiority over levofloxacin in this trial.
News For CBST From The Last 14 Days
Check below for free stories on CBST the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 18, 2014
13:32 EDTCBSTCubist announces voluntarily recalling one Cubicin lot
Subscribe for More Information
April 8, 2014
11:03 EDTCBSTPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use